Abstract
With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Current Pharmaceutical Design
Title:Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Volume: 21 Issue: 31
Author(s): Yong-Dong Kim, Tae-Eun Park, Bijay Singh, Sushila Maharjan, Kye-Soo Cho, Kyoung Pyo Park, Yun-Jaie Choi, Rohidas B. Arote and Chong-Su Cho
Affiliation:
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Abstract: With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Export Options
About this article
Cite this article as:
Kim Yong-Dong, Park Tae-Eun, Singh Bijay, Maharjan Sushila, Cho Kye-Soo, Park Pyo Kyoung, Choi Yun-Jaie, Arote B. Rohidas and Cho Chong-Su, Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013192327
DOI https://dx.doi.org/10.2174/138161282131151013192327 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution
Current Genomics TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets The Role of Natural Products in the Ligand Deorphanization of TRP Channels
Current Pharmaceutical Design Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Evaluation of Osteoporosis Risk Associated with Chronic Use of Morphine, Fentanyl and Tramadol in Adult Female Rats
Current Drug Safety Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Critical Steps in Tissue Processing in Histopathology
Recent Patents on DNA & Gene Sequences Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Signal Transduction Pathways of Taxanes-Induced Apoptosis
Current Medicinal Chemistry - Anti-Cancer Agents Oleic Acid Protects Against Oxidative Stress Exacerbated by Cytarabine and Doxorubicin in Rat Brain
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Jun Dimerization Protein 2: A Multifunctional Transcription Factor in Mammalian Cells
Current Genomics